Phase III
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
A federal judge has ruled that a decade’s worth of unpublished clinical trial data from drug companies, universities and other agencies involved, must now be made public.
BioSpace takes a look at some of the investigational products that could, one day, provide relief for migraine sufferers.
Exblifep is a combination of a novel extended-spectrum beta-lactamase inhibitor, enmetazobactam, and the fourth-generation cephalosporin cefepime.
Mid-February had a solid number of clinical trial announcements. Here’s a look.
The trial shows that the drug decreased the mortality rate of stroke from 19% to 11%.
Teva’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and business operations.
It was a very busy week for clinical trial news. Here’s a look.
Now that global responses are fully mobilized, what is being done to identify and develop drugs and vaccines against this novel coronavirus?
PRESS RELEASES